BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30522044)

  • 1. Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer.
    Surov A; Meyer HJ; Wienke A
    Transl Oncol; 2019 Feb; 12(2):375-380. PubMed ID: 30522044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations Between Imaging Biomarkers and Proliferation Index Ki-67 in Lymphomas: A Systematic Review and Meta-Analysis.
    Meyer HJ; Wienke A; Surov A
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e266-e272. PubMed ID: 31000497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized Uptake Values Derived from
    Surov A; Meyer HJ; Wienke A
    Contrast Media Mol Imaging; 2018; 2018():9257929. PubMed ID: 29983647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Imaging Parameters Provide Information Regarding Histopathology in Head and Neck Squamous Cell Carcinoma? A Meta-Analysis.
    Surov A; Meyer HJ; Wienke A
    Transl Oncol; 2018 Apr; 11(2):498-503. PubMed ID: 29510360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations Between FDG PET and Expression of VEGF and Microvessel Density in Different Solid Tumors: A Meta-analysis.
    Surov A; Wienke A
    Acad Radiol; 2021 Apr; 28(4):e110-e117. PubMed ID: 32327296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations Between [
    Surov A; Meyer HJ; Höhn AK; Winter K; Sabri O; Purz S
    Mol Imaging Biol; 2019 Apr; 21(2):368-374. PubMed ID: 29931433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer.
    Mohamadien NRA; Sayed MHM
    Nucl Med Commun; 2021 Jun; 42(6):656-664. PubMed ID: 33560720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET correlates weakly with HIF-1
    Surov A; Schmidt SA; Prasad V; Beer AJ; Wienke A
    Acta Radiol; 2021 Apr; 62(4):557-564. PubMed ID: 32551804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.
    Koo HR; Park JS; Kang KW; Han W; Park IA; Moon WK
    Eur Radiol; 2015 Nov; 25(11):3314-21. PubMed ID: 25903708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [¹⁸F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: usefulness of different quantitative methods of tumor proliferation.
    Marti-Climent JM; Dominguez-Prado I; Garcia-Velloso MJ; Boni V; Peñuelas I; Toledo I; Richter JA
    Rev Esp Med Nucl Imagen Mol; 2014; 33(5):280-5. PubMed ID: 25066253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parameters of simultaneous 18F-FDG-PET/MRI predict tumor stage and several histopathological features in uterine cervical cancer.
    Surov A; Meyer HJ; Schob S; Höhn AK; Bremicker K; Exner M; Stumpp P; Purz S
    Oncotarget; 2017 Apr; 8(17):28285-28296. PubMed ID: 28423698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volume-based parameters on FDG PET may predict the proliferative potential of soft-tissue sarcomas.
    Kitao T; Shiga T; Hirata K; Sekizawa M; Takei T; Yamashiro K; Tamaki N
    Ann Nucl Med; 2019 Jan; 33(1):22-31. PubMed ID: 30196378
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Romine PE; Peterson LM; Kurland BF; Byrd DW; Novakova-Jiresova A; Muzi M; Specht JM; Doot RK; Link JM; Krohn KA; Kinahan PE; Mankoff DA; Linden HM
    Breast Cancer Res; 2021 Aug; 23(1):88. PubMed ID: 34425871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Tumor Burden Assessed by Dual Time Point [
    Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
    Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
    Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
    J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Simultaneous
    Huang Z; Li X; Wang Z; Meng N; Fu F; Han H; Li D; Bai Y; Wei W; Fang T; Feng P; Yuan J; Yang Y; Wang M
    J Magn Reson Imaging; 2022 Jul; 56(1):63-74. PubMed ID: 34888990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships of
    Sengoz T; Karakaya YA; Gultekin A; Yaylali O; Senol H; Yuksel D
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(1):32-38. PubMed ID: 34991834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability of
    Jena A; Taneja S; Singh A; Negi P; Sarin R; Das PK; Singhal M
    AJR Am J Roentgenol; 2017 Sep; 209(3):662-670. PubMed ID: 28678576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MA; González Ageitos A; Muñoz Sánchez Mdel M; León Martín A; Espinosa Aunión R; Relea Calatayud F; Muñoz Madero V; Chacón López-Muñiz I; Cordero García JM; Jiménez Londoño GA
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):72-9. PubMed ID: 23053321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.